Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit

Aviv Gazit, Kevin Yee, Andrea Uecker, Frank D. Böhmer, Tobias Sjöblom, Arne Östman, Johannes Waltenberger, Gershon Golomb, Shmuel Banai, Michael Heinrich, Alexander Levitzki

    Research output: Contribution to journalArticle

    57 Citations (Scopus)

    Abstract

    Here we report on novel quinoxalines as highly potent and selective inhibitors of the type III receptor tyrosine kinases PDGFR, FLT3, and KIT. These compounds, tricyclic quinoxalines, were generated in order to improve bioavailability over the highly hydrophobic bicyclic quinoxalines. Four of the highly active compounds were characterized in detail and are shown to inhibit PDGFR kinase activity of the isolated receptor as well as in intact cells in the sub-micromolar concentration range. We show that the most active inhibitor (compound 13, AGL 2043) is ∼15-20 times more potent than its isomer (compound 14, AGL 2044). We therefore compared the three dimensional structures of the two compounds by X-ray crystallography. These compounds are also highly effective in blocking the kinase activity of FLT3, KIT, and the oncogenic protein Tel-PDGFR in intact cells. These compounds are potent inhibitors of the proliferation of pig heart smooth muscle cells. They fully arrest the growth of these cells and the effect is fully reversible. The chemical, biochemical and cellular properties of these compounds as well as the solubility properties make them suitable for development as anti-restenosis and anti-cancer agents.

    Original languageEnglish (US)
    Pages (from-to)2007-2018
    Number of pages12
    JournalBioorganic and Medicinal Chemistry
    Volume11
    Issue number9
    DOIs
    StatePublished - May 1 2003

    Fingerprint

    Quinoxalines
    Phosphotransferases
    Cells
    X ray crystallography
    X Ray Crystallography
    Receptor Protein-Tyrosine Kinases
    Cardiac Myocytes
    Isomers
    Solubility
    Biological Availability
    Smooth Muscle Myocytes
    Muscle
    Swine
    Growth
    Neoplasms
    Proteins

    ASJC Scopus subject areas

    • Biochemistry
    • Molecular Biology
    • Organic Chemistry
    • Drug Discovery
    • Pharmaceutical Science

    Cite this

    Gazit, A., Yee, K., Uecker, A., Böhmer, F. D., Sjöblom, T., Östman, A., ... Levitzki, A. (2003). Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorganic and Medicinal Chemistry, 11(9), 2007-2018. https://doi.org/10.1016/S0968-0896(03)00048-8

    Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. / Gazit, Aviv; Yee, Kevin; Uecker, Andrea; Böhmer, Frank D.; Sjöblom, Tobias; Östman, Arne; Waltenberger, Johannes; Golomb, Gershon; Banai, Shmuel; Heinrich, Michael; Levitzki, Alexander.

    In: Bioorganic and Medicinal Chemistry, Vol. 11, No. 9, 01.05.2003, p. 2007-2018.

    Research output: Contribution to journalArticle

    Gazit, A, Yee, K, Uecker, A, Böhmer, FD, Sjöblom, T, Östman, A, Waltenberger, J, Golomb, G, Banai, S, Heinrich, M & Levitzki, A 2003, 'Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit', Bioorganic and Medicinal Chemistry, vol. 11, no. 9, pp. 2007-2018. https://doi.org/10.1016/S0968-0896(03)00048-8
    Gazit, Aviv ; Yee, Kevin ; Uecker, Andrea ; Böhmer, Frank D. ; Sjöblom, Tobias ; Östman, Arne ; Waltenberger, Johannes ; Golomb, Gershon ; Banai, Shmuel ; Heinrich, Michael ; Levitzki, Alexander. / Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. In: Bioorganic and Medicinal Chemistry. 2003 ; Vol. 11, No. 9. pp. 2007-2018.
    @article{110a833a990f4a8e8f1439d9ee9f6f33,
    title = "Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit",
    abstract = "Here we report on novel quinoxalines as highly potent and selective inhibitors of the type III receptor tyrosine kinases PDGFR, FLT3, and KIT. These compounds, tricyclic quinoxalines, were generated in order to improve bioavailability over the highly hydrophobic bicyclic quinoxalines. Four of the highly active compounds were characterized in detail and are shown to inhibit PDGFR kinase activity of the isolated receptor as well as in intact cells in the sub-micromolar concentration range. We show that the most active inhibitor (compound 13, AGL 2043) is ∼15-20 times more potent than its isomer (compound 14, AGL 2044). We therefore compared the three dimensional structures of the two compounds by X-ray crystallography. These compounds are also highly effective in blocking the kinase activity of FLT3, KIT, and the oncogenic protein Tel-PDGFR in intact cells. These compounds are potent inhibitors of the proliferation of pig heart smooth muscle cells. They fully arrest the growth of these cells and the effect is fully reversible. The chemical, biochemical and cellular properties of these compounds as well as the solubility properties make them suitable for development as anti-restenosis and anti-cancer agents.",
    author = "Aviv Gazit and Kevin Yee and Andrea Uecker and B{\"o}hmer, {Frank D.} and Tobias Sj{\"o}blom and Arne {\"O}stman and Johannes Waltenberger and Gershon Golomb and Shmuel Banai and Michael Heinrich and Alexander Levitzki",
    year = "2003",
    month = "5",
    day = "1",
    doi = "10.1016/S0968-0896(03)00048-8",
    language = "English (US)",
    volume = "11",
    pages = "2007--2018",
    journal = "Bioorganic and Medicinal Chemistry",
    issn = "0968-0896",
    publisher = "Elsevier Limited",
    number = "9",

    }

    TY - JOUR

    T1 - Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit

    AU - Gazit, Aviv

    AU - Yee, Kevin

    AU - Uecker, Andrea

    AU - Böhmer, Frank D.

    AU - Sjöblom, Tobias

    AU - Östman, Arne

    AU - Waltenberger, Johannes

    AU - Golomb, Gershon

    AU - Banai, Shmuel

    AU - Heinrich, Michael

    AU - Levitzki, Alexander

    PY - 2003/5/1

    Y1 - 2003/5/1

    N2 - Here we report on novel quinoxalines as highly potent and selective inhibitors of the type III receptor tyrosine kinases PDGFR, FLT3, and KIT. These compounds, tricyclic quinoxalines, were generated in order to improve bioavailability over the highly hydrophobic bicyclic quinoxalines. Four of the highly active compounds were characterized in detail and are shown to inhibit PDGFR kinase activity of the isolated receptor as well as in intact cells in the sub-micromolar concentration range. We show that the most active inhibitor (compound 13, AGL 2043) is ∼15-20 times more potent than its isomer (compound 14, AGL 2044). We therefore compared the three dimensional structures of the two compounds by X-ray crystallography. These compounds are also highly effective in blocking the kinase activity of FLT3, KIT, and the oncogenic protein Tel-PDGFR in intact cells. These compounds are potent inhibitors of the proliferation of pig heart smooth muscle cells. They fully arrest the growth of these cells and the effect is fully reversible. The chemical, biochemical and cellular properties of these compounds as well as the solubility properties make them suitable for development as anti-restenosis and anti-cancer agents.

    AB - Here we report on novel quinoxalines as highly potent and selective inhibitors of the type III receptor tyrosine kinases PDGFR, FLT3, and KIT. These compounds, tricyclic quinoxalines, were generated in order to improve bioavailability over the highly hydrophobic bicyclic quinoxalines. Four of the highly active compounds were characterized in detail and are shown to inhibit PDGFR kinase activity of the isolated receptor as well as in intact cells in the sub-micromolar concentration range. We show that the most active inhibitor (compound 13, AGL 2043) is ∼15-20 times more potent than its isomer (compound 14, AGL 2044). We therefore compared the three dimensional structures of the two compounds by X-ray crystallography. These compounds are also highly effective in blocking the kinase activity of FLT3, KIT, and the oncogenic protein Tel-PDGFR in intact cells. These compounds are potent inhibitors of the proliferation of pig heart smooth muscle cells. They fully arrest the growth of these cells and the effect is fully reversible. The chemical, biochemical and cellular properties of these compounds as well as the solubility properties make them suitable for development as anti-restenosis and anti-cancer agents.

    UR - http://www.scopus.com/inward/record.url?scp=0037401818&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0037401818&partnerID=8YFLogxK

    U2 - 10.1016/S0968-0896(03)00048-8

    DO - 10.1016/S0968-0896(03)00048-8

    M3 - Article

    VL - 11

    SP - 2007

    EP - 2018

    JO - Bioorganic and Medicinal Chemistry

    JF - Bioorganic and Medicinal Chemistry

    SN - 0968-0896

    IS - 9

    ER -